#1 Clinical Trials Search in Europe

Quc398

A groundbreaking clinical trial is underway to investigate the potential benefits of QUC398, a new drug designed to address knee osteoarthritis. This study aims to evaluate the drug’s effectiveness in reducing pain, preserving cartilage, and improving overall knee function in patients suffering from this common joint condition. The trial’s results could pave the way for a novel treatment option for those struggling with knee osteoarthritis.

Table of Contents

What is QUC398?

QUC398 is an investigational treatment currently being studied for its potential benefits in treating knee osteoarthritis. An investigational treatment means it’s a new medication that is still being tested and is not yet approved for widespread use. Researchers are conducting trials to determine if QUC398 is safe, effective, and well-tolerated by patients.[1]

What Condition Does QUC398 Treat?

QUC398 is specifically being studied for the treatment of knee osteoarthritis. Osteoarthritis is a common joint condition that causes pain, stiffness, and reduced mobility. In knee osteoarthritis, the cartilage in the knee joint breaks down over time, leading to pain and difficulty with everyday activities.[1]

How is QUC398 Administered?

QUC398 is administered as a subcutaneous injection. This means it’s injected just under the skin, not into a vein or muscle. The current study uses a solution of 150 mg/mL, with two injections given per dose to reach a total of 300 mg. These injections are given every four weeks, which is referred to as “q4w” in medical terms.[1]

Current Clinical Trial

A clinical trial is currently underway to test QUC398. Here are some key points about the trial:

  • Type of study: This is a Phase IIa study, which means it’s an early stage of testing in humans to see if the treatment is effective and safe.
  • Study design: It’s a randomized, placebo-controlled, blinded study. This means that participants are randomly assigned to either receive QUC398 or a placebo (a substance with no active ingredients), and neither the participants, investigators, nor the sponsor know who is receiving which treatment.
  • Duration: The study appears to last for 52 weeks (one year), with various assessments done throughout this period.

This careful study design helps ensure that the results are as accurate and unbiased as possible.[1]

Expected Benefits of QUC398

The researchers are investigating whether QUC398 can provide two main benefits for people with knee osteoarthritis:

  1. Pain relief: One of the primary goals is to see if QUC398 can effectively reduce knee pain associated with osteoarthritis.
  2. Cartilage preservation: Researchers are also studying whether QUC398 can help preserve knee cartilage, which could potentially slow down the progression of osteoarthritis.

If successful, QUC398 could offer a new treatment option for people suffering from knee osteoarthritis, potentially improving their quality of life and daily functioning.[1]

How Researchers Measure QUC398’s Effectiveness

To determine if QUC398 is effective, researchers are using several measurement tools:

  • KOOS (Knee Injury and Osteoarthritis Outcome Score): This is a questionnaire that assesses various aspects of knee health, including pain, other symptoms, daily function, sports activities, and quality of life.
  • Pain NRS (Numerical Rating Scale): This is a simple scale where patients rate their pain intensity from 0 to 10.
  • Cartilage volume measurements: Special imaging techniques are used to measure the amount of cartilage in the knee joint.
  • PGA (Patient’s Global Assessment): This is a measure where patients rate their overall condition.

These tools help researchers understand how well QUC398 is working to relieve pain, improve function, and potentially slow down the progression of osteoarthritis.[1]

Aspect Details
Study Type Phase IIa, randomized, placebo-controlled, blinded
Drug QUC398 (300 mg dose)
Condition Knee Osteoarthritis
Administration Subcutaneous injection, every 4 weeks
Primary Outcome Change in KOOS Pain subscale at Week 12
Secondary Outcomes Cartilage preservation, pain relief over time, overall knee function
Study Duration 52 weeks

FAQ

  • What is QUC398 and how is it administered? QUC398 is an investigational treatment for knee osteoarthritis. It is administered as a solution for subcutaneous injection, with two 1 mL injections of 150 mg/mL given per dose to complete the 300 mg treatment.
  • How often are the QUC398 injections given? The injections are given every four weeks (q4w) throughout the study period.
  • What is the main goal of this clinical trial? The main goal is to determine if QUC398 has beneficial effects on osteoarthritis knee pain and knee cartilage, and to assess its safety and tolerability.
  • How long does the study last? The study lasts for 52 weeks (1 year), with various assessments conducted throughout this period.
  • What are some of the key outcomes being measured in this trial? Key outcomes include changes in knee pain (measured by the KOOS Pain subscale), cartilage volume preservation, overall knee function, and the patient's global assessment of their condition.

Ongoing Clinical Trials on Quc398

  • Study on the Effects of QUC398 for Patients with Knee Osteoarthritis

    Not recruiting

    2 1 1
    Investigated drugs:
    Denmark France Spain

Glossary

  • Osteoarthritis (OA): A common joint condition characterized by the breakdown of cartilage, causing pain, stiffness, and reduced mobility.
  • Subcutaneous (s.c.) injection: An injection given into the layer of fat just beneath the skin.
  • Placebo: An inactive substance used as a control in clinical trials to compare against the effects of the investigational drug.
  • KOOS (Knee Injury and Osteoarthritis Outcome Score): A standardized questionnaire used to assess patients' opinions about their knee and associated problems.
  • Cartilage: A flexible connective tissue found in joints that acts as a cushion between bones.
  • NRS (Numerical Rating Scale): A tool used to measure pain intensity on a scale, typically from 0 to 10.
  • Patient's Global Assessment (PGA): A measure of a patient's overall perception of their disease status or health condition.
  • Phase IIa study: An early stage of clinical research that aims to establish the effectiveness and safety of a new drug in a small group of patients with the target condition.

References